Citius Pharmaceuticals, Inc..
CTXR.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing critical care products, with a focus on anti-infective products in particular. The company's lead product candidate is Mino-Lok, an antibiotic lock solution used to treat patients with cath...Show More
Better Health for All
0
Citius Pharmaceuticals' LYMPHIR™, an FDA-approved immunotherapy for relapsed or refractory cutaneous T-cell lymphoma, has a significant safety record.
1
Clinical trial data showed capillary leak syndrome (CLS) in 27% of patients, including one fatal case, visual impairment in 9%, and infusion-related reactions in 69%.
2
The product carries a boxed warning for CLS and visual impairment, and the FDA has a postmarketing requirement to characterize the risk of visual impairment.
3
Despite these severe risks, the company has disclosed this safety information, including the boxed warnings, and rolled out education programs for medical professionals and an information platform.
4
The company's other products demonstrate positive health impacts. Mino-Lok, an antibiotic lock solution for catheter-related bloodstream infections, showed statistically significant improvement in time to catheter failure and overall treatment success (57.1% vs 37.7% for control) in a Phase 3 trial, with no drug-related serious adverse events.
5
Halo-Lido for hemorrhoids showed 42% of high-dose patients reaching a meaningful change threshold, with no serious adverse events reported.
6
The company's entire business is dedicated to developing and commercializing critical care products and innovative solutions for unmet medical needs, with all products aiming for positive health outcomes. As a pharmaceutical company, its R&D is entirely focused on health improvement, including developing a novel Patient Reported Outcome instrument and a first novel targeted systemic therapy for CTCL.
7
, 3 However, the company's focus is overwhelmingly on treatment, with no evidence of investment in disease prevention or health promotion initiatives. The company holds patents for Mino-Lok until 2036 and for Halo-Lido until 2044, and is exploring international licensing partnerships for LYMPHIR, but there is no information regarding patent flexibility or access programs.
8
, 2, 0
Fair Money & Economic Opportunity
0
No evidence available to assess Citius Pharmaceuticals, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess Citius Pharmaceuticals, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Citius Pharmaceuticals, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-40
The company has a formal whistleblower policy established by the Audit and Risk Committee, which includes procedures for confidential, anonymous submission of complaints regarding accounting or auditing matters and prohibits retaliation.
1
However, there is no explicit evidence of independent investigation processes or specific timelines for resolution. The Board of Directors has determined that all directors are independent, except for the Chief Executive Officer and Chairman, and the Executive Vice Chairman, due to their employment with the company.
2
With 8 directors in total, this means 75% of the board is conflict-free. The company has adopted a written Code of Ethics and Business Conduct that applies to directors, officers, and all employees, promoting compliance with applicable laws and prohibiting unfair dealing practices.
3
However, the articles do not provide specific details on FCPA compliance, training frequency, or effectiveness metrics for this policy.
Kind to Animals
-50
Citius Pharmaceuticals' product development involves animal testing, as evidenced by FDA agreement for a large animal pharmacology study and a 28-day toxicology study for Mino-Wrap.
1
The company's policy implicitly allows for animal testing where legally mandated, aligning with a score of -50.
2
Furthermore, the company uses animal-derived ingredients, with Mino-Wrap being comprised of porcine gelatin, indicating a reliance on animal agriculture without any evidence of ethical practices, humane certifications, or efforts to replace such inputs, leading to a score of -100 for animal agriculture ethics.
3
No War, No Weapons
0
No evidence available to assess Citius Pharmaceuticals, Inc. on No War, No Weapons.
Planet-Friendly Business
20
The company's total Scope 1, 2, and 3 greenhouse gas emissions are 1,850 metric tons CO2e.
1
It diverts 68% of its waste from landfill.
2
Respect for Cultures & Communities
0
No specific, quantifiable evidence was found in the provided articles for any of the KPIs related to 'Respect for Cultures & Communities'. Information regarding partnerships, community investments, cultural incidents, or specific protocols was not available or not presented in a manner that aligns with the rubric's quantitative thresholds.
Safe & Smart Tech
0
The company files with the SEC, including annual reports (10-K filings) from 2011 to 2024, and engages with the U.S. Food and Drug Administration (FDA) regarding its products.
1
It references sections of the Securities Act of 1933 and the Securities Exchange Act of 1934.
2
The company also states compliance with federal and state trademark laws, and its website is protected by U.S. and foreign copyright laws.
3
Zero Waste & Sustainable Products
0
No evidence available to assess Citius Pharmaceuticals, Inc. on Zero Waste & Sustainable Products.